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Abstract 
Background: THilnahyroid cancer is a cancer that starts in the thyroid gland and thought to be 
related to a number of environmental and genetic predisposing factors .Human Papil- loma Virus 
(HPV) the virus that causes cervical cancer ,is also linked to throat cancer and is one among 
their associated infective agents. 
Objective: This study aimed at detecting DNA of HPV genotype-18 using in situ 
hybridization technique in thyroid tissues from benign thyroid hyperplasia and thyroid car- 
cinoma, and elucidate the association between this HPV-18 and thyroid carcinogenesis. 
Patients and Methods: Sixty (60) formalin-fixed, paraffin embedded thyroid tissue blocks 
were obtained ,among them (30) tissue biopsies from thyroid carcinoma with grade I and (20) 
benign thyroid neoplasm tissue blocks as well as (10) autopsies from apparently normal thyroid 
tissues were collected from the archives of Forensic Medicine Institute / Babil and used as thyroid 
healthy control group. Detection of HPV-18 was done by using highly sensitive version of in situ 
hybridization technique. 
Results: Among malignant thyroid tumors 56.7% patients had HPV-18 while 35% HPV- 18 
positivity was detected in benign thyroid tumor group. None of healthy thyroid tissues revealed 
ISH reactions. There was 32.7% female had HPV-18, and 24% male had HPV-18. No significant 
statistical associations were noticed between the presence of HPV-18 and the age of those 
patients. 
Conclusion: Human Papilloma virus genotype-18 could share a role in pathogenesis of this 
group of patients with thyroid cancers. 
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1. Introduction 
Thyroid cancer is the most common cancer of the endocrine organs 
accounting for up to 2.5% of all malignancies [1] [2]. 
Incidence is, in fact, rising faster than all cancers, where females are more 
frequently affected than males. It is thought that this is in part the result of 
earlier detection; however, the increase in mortality as well as the increase in 
incidence of larger thyroidtumors suggests that there may be additional factors 
behind this increase [3]. 
The majority of thyroid cancers develop from follicular epithelial cells and 
according to their morphology and biology They are divided grossly into two 
groups; the first group, well differentiated thyroid cancers, which include the 
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usually slowly growing papillary thyroid carcinoma (PTC) and the follicular 
thyroid carcinoma (FTC). The PTC accounts for approximately up to 80% of 
thyroid tumours, whereas the FTC accounts for 5-15% of diagnosed thyroid 
malignancies [4]. These cancers are usually curable and in contrast to the 
second group which compromises the anaplastic thyroid cancers (ATC), which 
represent the poorly differentiated thyroid cancers and comprises only 1-2% of 
all diagnosed thyroid malignancies [5]. ATC is characterized by rapid and 
invasive growth resulting in fulminant disease course and poor outcome .In 
thyroid, approximately 5% of thyroid malignancies are diagnosed as medullary 
carcinoma, which in turn originates from the para follicular C cells [6]. 
From 2000 to 2009, incidence rates among men have decreased for five of 
the 17 most common cancers: prostate, lung-bronchus, colorectal, stomach, 
and larynx. In contrast, rates among men during the same time interval 
increased for six cancers: kidney, pancreas, liver, thyroid, melanoma of the 
skin, and myeloma. Among women, incidence rates have decreased from 2000 
to 2009 for seven of the 18 most common cancers: lung, colorectal, urinary 
bladder, cervix uteri, oral cavity and pharynx (all tumors regardless of their 
potential association with HPV infection), ovary, and stomach. Incidence rates 
among women have increased from 2000 to 2009 for seven cancers: thyroid, 
melanoma, kidney, pancreas, leukemia, liver, and uterus [6] . 
Today, more than 200 types of HPVs have been reported, which are 
classified into low –oncogenic risk and high- oncogenic risk types according to 
their associations with malignant tumors [7]. 
High oncogenic risk HPV types may be integrate into the host cell 
chromosome, here they interrupt the integration of E2 gene that regulates the 
transcription & expression of HPV-E6 & E7 oncoproteins. The E6 and E7 genes 
represent transforming genes and their products are responsible for the 
alteration of growth patterns of the infected cells as well as acting, at least in 
part, by interfering with host cell control of transcription and the cell cycle [8]. 
Although there are approximately a dozen oncogenic HPV types, HPV 16 and 
18 are the most common HPV types and are found in approximately 70% of 
cervical cancers. Human Papilloma virus 16 is found in approximately 90% of 
the non-cervical cancers that are often associated with HPV infection [9]. 
Experts have long suspected a link between HPV and oro-pharyngeal 
cancer (OPC) with an increasing body of evidence supporting this association. 
A case-control study of 100 patients with newly diagnosed oro-pharyngeal 
cancers (as compared to 200 matched controls) has found HPV-16 strain in 
72% of these cancerous tumors [10]. Recent trends continue speculation that by 
2020 year HPV will cause more cases of oro-pharyngeal cancers each year than 
cervical cancers [11]. 
Exposure to HPV is common through sexual contact, and most infections 
resolve over time. However, persistent infection with oncogenic HPV types is 
etiologically linked to cervical cancer [12], as well as cancers of the oropharynx 
[13], anus [14], vagina and vulva [15], and penis [16]. Virtually, all cervical 
cancers are due to HPV infection, along with 90% of anal cancers, more than 
60% of certain subsets of oro-pharyngeal cancers, and 40% of vagina, vulva, and 
penile cancers [9]. 
Oral HPV16 & 18 DNA are common among female patients with HPV-
OPC, but not among their spouses. Spouses of HPV-OPC female patients may 
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have an elevated risk or history of cervical cancer [17]. 
This research work, and up to our best knowledge, is the first in Iraq, that 
study the percentage of HPV18 genotype in a group of Iraqi patients with 
thyroid lesions. 
 
2. Materials and methods 
The study was designed as a retrospective one. It has recruited 60 selected 
formalin fixed, paraffin embedded thyroid tissue blocks were obtained ,among 
them (30) tissue biopsies with grade 1 invasive papillary thyroid carcinoma and 
(20) benign thyroid tissue blocks as well as (10) apparently normal thyroid 
tissue autopsies which were collected from the archives of Forensic Medicine 
Institute / Babylon and were used as thyroid healthy control groups. The 
diagnosis of these tissue blocks were based on their accompanied records. A 
consultant pathologist reexamined all these cases to further confirm the 
diagnosis following trimming process of these tissue blocks. 
On the one hand, the detection of HPV18 by ISH kit (Zyto Vision GmbH. 
Fischkai, Bremerhaven. Germany) was performed on 4µm paraffin embedded 
tissue sections using digoxigenin-labeled oligo-nucleotidesprobe which targets 
HPV18 DNA. One section was mounted on ordinary glass slide and stained 
with hematoxyline and eosin, while another slide was mounted on charged 
slide to be used for ISH for detection of HPV18. 
For the in situ hybridization procedure, the slides were placed in 60c hot-air 
oven over night then the tissue sections were de-paraffinized and then treated 
by graded alcohols according to the standard methods and the details of 
processes for performing ISH reaction with this probe were applied according the 
instructions of the manufacturing company(Zyto Vision GmbH. Fischkai, 
Bremerhaven. Germany). The main steps for ISH procedure are: 
Incubation of slides for min at 70◦C(e.g.  on hot plate), then Incubation of 
slides for 5 
min in xylene. After that incubation for 5 min in 100% ethanol 
(alternatively, dewaxing protocols routinely used in immunohistochemistry 
procedures, e.g.  2-5 min xylene, 2-5 min 100% ethanol, 2-5 min 96% ethanol, 1-5 
min 70% ethanol, can be used. Air drying of sections. Then application 
(dropwise) Pepsin Solution(ES1) to the tissue/cell section and incubate for 20-
30 min at 37◦C in a humidity chamber. After that we immersed slides in 
distilled water and drain off the water, air dried sections, then we add the 
probe to the center of a cover slip and place cover slip upside down on target 
area). Denaturation of the slides at 75◦C for 5 min, e.g. on hot plate, then are 
transferred the slides to a humidity chamber and hybridize for 60 min at 37◦C 
for DNA-targeting probes or at 55◦C for RNA- targeting probes) and the post-
hybridization and detection process that included removing the cover slip by 
submerging in 1x wash buffer TBS, then washed for 5 min in 1x wash 
B\buffer TBS (prepared by using WB5) at 55◦C (should not perform this step on 
slides hybridized with Zytofast RNA (+) control probe(PF6) as this will reduce 
signal intensity). 
Then application of AP-Streptovidin (AB9) drop wise (3-4 drops per slide) 
to the slides and incubate for 30 min at 37◦C in a humidity chamber. Then they 
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were washed in wash buffer TBS (prepared by usingWB5) and then twice 
times for 1 min in distilled water and application of NBT/BCIP(SB4) drop wise 
(4 drops per slide) to the slides and incubated for 40 min at 37◦C in humidity 
chamber .Then the color development is checked in intervals of approx, 5-10 
min using microscope. Lastly, Slides were washed three times for min in 
distilled water. After that the sections are covered. Then the sections are 
embedded in an aqueous embedded medium, then by light microscope presents 
the final evaluation. 
Chi –square test was used to detect the significance between variables of 
our study . All the statistical analysis was done by SPSS program(Version– 
17)&P value was considered significant when p <0.05.Table-1- shows the 
consistency between the type of tumor of thyroid cancer and control group with 
gender by applying Chi-square test ,the P-value was P>0.05 of the three groups 
with gender .There was no differences between the presence of tumor and the 
gender. 
 
3. Results 
The results of HPV18- ISH among study groups 
It was found after application and analysis of (ISH) for detection of HPV-
18 DNA in the tissues obtained from patients with Thyroid cancer as well as 
benign Thyroidneoplasia that seventeen (17) out of thirty (30) patients with 
carcinoma of thyroid showed positive In Situ Hybrization reaction where it 
constituted 56.7% of the total thyroid tumor cases of this study (table 1 and 
figure 1). None of control group presented positive signals for HPV18-ISH 
test. However , in comparison to the percentage of HPV18- DNA in healthy 
control group as well as in the group of benign Thyroidneoplasia, the 
differences between the percentages of HPV18- DNA in tissues of patients 
with Thyroid cancers and each of these above mentioned groups are 
statistically very highly significant (P value = < 0,0001).  
 
Table (1): In Situ Hybridization for Detecting HPV18 – ISH in Tissues with 
Thyroid Tumors. 
 
Studied groups 
HPV18 -ISH Total Comparison of 
significant 
Positive Negative P-value Sig. 
Thyroid 
Cancer 
N 17 13 30   
 0.00 
 
(P≤0.01) % 56.7 43.3 100 
Benign 
Thyroid 
neoplasia 
N 7 13 20 
% 35 65 100 
Healthy 
control 
N 0 10 10 
% 0 100 100 
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Chi-square was done to test the scoring of HPV18-ISH signals of thyroid 
lesion (Table- 2& Figure 1), it was found that there was 47.1% thyroid lesions 
that had low scoring in malignant thyroid lesions group and 57.1% thyroid 
lesions had low scoring in benign thyroid lesions group. While there was 35.3% 
thyroid lesions have moderate scoring in malignant thyroid lesions group and 
42.9% thyroid lesions have moderate scoring in benign thyroid lesions group. 
Finally, there were 17.6% thyroid lesions that have strong scoring in malignant 
thyroid lesions group and none in benign thyroid lesions group. 
 
Table (2):Frequency Distribution of HPV 18 DNA-ISH Signal Scoring among the 
Malignant and Benign Thyroid Tumors. 
 
P 
Normal 
Thyroid 
Tissues 
(n=10) 
Benign Thyroid 
Tumors 
(n=20) 
Thyroid Tumors 
(n=30) 
 
HPV18Signal 
Scoring 
% N % N % N 
0.001  
 
100.0 10 65 13/20 43.3 13/30 Negative 
0.00 0 35 7/20 56.7 17/30 Positive 
0 0 57.1 4/7 47.1 8/17 I 
S
co
ri
n
g
 
0 0 42.9 3/7 35.3 6/17 II 
0 0 0.00 0 17.6 3/17 III 
 55.5  67.1  95.6 Mean Rank 
 
Chi-square was done for evaluation of signals intensities of HPV18-ISH results 
according to type of thyroid lesions (malignant thyroid lesions, benign thyroid 
lesions groups) (Table- 3& Figure -1),there was 52.9% thyroid lesions that had 
weak intensity in malignant thyroid lesions group and 57.1% thyroid lesions had 
weak intensity in benign thyroid lesion group. While there was 29.5% thyroid 
lesions have moderate intensity in malignant thyroid lesion group and 28.6% 
thyroid lesions have moderate intensity in benign thyroid lesions group. The 
percentage of patients that had high intensity signals of HPV18-ISH in 
malignant thyroid lesions group was 17.6% whereas there was 14.3% patients 
that had high intensity signals of HPV16-ISH in benign thyroid lesions group. 
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Table (3): Frequency of Signal Intensity of Positive HPV18 DNA- ISH Reactions. 
Chi-square 
Tests 
Negative 
HPV18 
signaling 
Signal Intensity positive 
HPV18 
signaling 
Studied 
Groups  High  Moderate Weak 
≤0.001 
significant 
13/30  
(43.3%) 
3/17 
 (17.6%) 
5/17 
(29.5%) 
9/17 
(52.9%) 
17/30 
(56.7%) 
Malignant 
Thyroid. 
Tumors 
(n=30) 
13/20 
 ( 65%) 
1/7 
 (14.3%) 
2/7 
 (28.6%) 
4/7 
 (57.1%) 
7/20 
 (35%) 
Benign 
Thyroid 
Tumors 
(n=20) 
10/10  
( 100%) 
0.00 
 (0.00%) 
0.00 
 (0.00%) 
0.00 
(0.00%) 
0.00  
(0.00%) 
Healthy 
Thyroid. 
Tissues 
 (n=10) 
 
 
 
 
A                                                              B
 
 
C                                                             D 
Figure(1) :In Situ Hybridization(ISH) for HPV-18 Deduction Infiltrative Thyroid 
Cancers Using Biotinylated -Labeled HPV-18 
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4. Discussion 
Head and neck cancers arise in the nasal cavity, sinuses, mouth, lips, 
salivary glands, throat, larynx and thyroid gland, are predominately squamous 
cell carcinomas. Globally, head and neck cancers are the sixth most common 
type of cancer, where more than 70% of cases occurring in developing 
countries. They are rare in the United States, accounting for 5% of all cancer 
cases. The majority of molecular events in the genesis of oral squamous cell 
carcinoma are unknown [18]. 
Although recent evidence has implicated viruses in the regulation of epithelial 
–to- mesenchymal transition and tumor progression, little is known regarding 
viral infections in thyroid malignancies [19]. 
In the current research, the rate of detection of positive results of HPV 18 
DNA-ISH reactions in the group of malignant thyroid tumors was 53.3 % (16 of 
total 30) while in the benign thyroid tumors was 27.3%(6 of total 22). 
To our best knowledge, this study is the first in Iraq that investigates the 
HPV18 genotype in a group of Iraq patients with malignant & benign thyroid 
lesions. Moreover, and on reviewing the available scientific research works in 
this entity, we found an extreme shortage of the articles in this respect. However, 
the present results are in disagreement with a work done by [18], who have 
examined and who did not able to find HPV-DNA on examination of their but 
were not able to find HPV-DNA in the examined thyroid lesions. 
Regarding the copy number of viral infection in the examined thyroid 
lesions of this study, we found signal scoring is refers to the wide spread of the 
viral invasion in relation to the surface area of the examined tissues. However, 
the present study has found an in equal percentage of distribution of the 3 scores 
of HPV-ISH in the examined thyroid tissues. 
Uterine cancer ranked fourth among women of each racial and ethnic group 
except API women, in whom thyroid cancer was the fourth most common 
cancer. Beyond the three commonly diagnosed cancers for men and four most 
commonly diagnosed cancers for women, cancers ranking have varied by race and 
ethnicity [11]. 
Despite great variability in the HPV detection rates worldwide, the 
majority of HPV types that have been detected were the high oncogenic risk 
group (HPV -16 & HPV-18) [19]. 
By analogy, it was found that the present findings of HPV18 in Iraqi 
patients with thyroid cancers have an equal proportions of consistency to 
those studies done in Iraq  by  [20] [21] [22] [23] [24] who found that the HPV 
16 &18 as the most prevalent  type   in their studied group of patients with 
cervical, esophageal, oral, prostate and breast can- cers, respectively. However, 
other types of HPV, such as HPV18, 31 and 33 were found to have probable 
roles in such cancers. High-risk HPV encodes a series of proteins, some of 
which have oncogenic potential [25]. 
Although it is known and widely accepted for many years that integration 
of DNA of high-risk HPV types into cellular genome as the major contributing 
factor in cervical carcinogenesis [26], recently is also linked to a common head & 
neck cancers [27]. The transmission routes of HPV detected in thyroid cancers 
are still unclear. However, the researchers have indicated that infection with 
HPV is a risk factor for oro-pharyngeal carcinoma (OPC). HPV is most 
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commonly passed from person to person during sexual activity, including oral 
intercourse. However, the risk of developing HPV-positive OPC is low for 
spouses ( 1).HPV is most commonly passed from person to person during sexual 
activity, including oral inter- course. Michael Douglas [28] recently related 
HPV16-associated throat cancer to oral sex as a possible cause of their studied 
throat cancers. High viral load of HPV has been associated with the 
microscopical diagnosis of a concurrent lesions as well as an indication to 
progress to precancer and cancer [29]. Studies concerning HPV association 
with cancer, especially cervical cancers, have revealed that an increase in HPV 
load is significantly associated with cervical carcinoma. [30] [31]. However, it 
has been well documented that the episomal viral DNA frequently integrates into 
the host genome as HPV-infected lesions progress to cervical cancer [32]. High 
proliferation of the infected host tissues has been considered to be crucial for the 
persistence of HPV that infects a basal layer cell of the cervical stratified 
squamous epithelium, the HPV DNA only replicated during cell divisions of the 
host before the differentiation of the infected cells. This allow the copies of viral 
DNA preserves in a large number in premature cells. In a similar way, infection 
of mammary epithelial cells ,that partly loses control in proliferation the HPV 
DNA copies may be preserved in nearly every clone of its first host that may 
further interact with other carcinogenic factors and involve in the later 
carcinogenic steps of breast cancer [33]. In an infected cell, vegetative viral 
replication end- ing with the release of the virus from cell, where this is definitely 
against its transformation into a malignant one [34]. Only E6 and E7 genes 
remain in the host genome during HPV DNA integration and therefore, their 
presence in tumor tissues may better represent the real HPV participation in 
carcinogenesis [32]. Although in the present study, a respective percentage of 
HPV-18 infection was found in tissues obtained from thyroid cancers as well as a 
highest percentage of HPV-18 ISH – reactions with low signal scoring, for this 
reason, ISH signals of HPV DNA ought to be of low intensity while the high 
intensity could reflect and indicate for viral replication inside the cells and is as 
such have rush an additional conflict for HPV participation in thyroid cancer and 
more researches could be forwarded to explore their actual role in that 
carcinogenesis .The fact that we have not found the Human Papilloma viral 
DNA in healthy thyroid specimens could support, to certain extent, the 
hypothesis that the virus might play a role in the etiology of thyroid cancer in 
only a sub set of population of patients. On the other hand, it is logical to 
believe that the presence of high-risk types of HPV alone is not sufficient to 
implement full process of tumorigenesis and that further changes should be 
accumulated over time in a step-wise manner to cause the disease. It could be 
concluded from the present results that Human Papilloma virus genotype-18 
could share a role in pathogenesis of this group of patients with thyroid cancers. 
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 الخلاصة
 تربط  : سرطان الغدة الدرقية هو السرطان الذي يبدأ في الغدة الدرقية و التي يعتقد أنها مرتبطة بتهيئة عدد من العوامل البيئية و الوراثيةخلفية علمية
العوامل المعدية ذات  والذي يعد واحد منلسرطان الحنجرة  المسببيعتبر  المسبب لسرطان عنق الرحم ، وأيضا )VPH( suriV amollipaP namuH
 الصلة.
في  euqinhcet noitazidirbyh utisباستخدام تقنية   81-suriV amollipaP namuH: تهدف هذه الدراسة للكشف عن الحمض النووي ل  الهدف
وسرطان  81-VPHالورم الناجم عن أنسجة الغدة الدرقية المأخوذة من تضخم الغدة الدرقية الحميد و سرطان الغدة الدرقية ، و توضيح العلاقة بين هذا 
 الغدة الدرقية.
) 03، وتم الحصول على أنسجة الغدة الدرقية كالتالي، من بينهم (  niffarap dexif-nilamrofعينة من  ) 06: ستين (  المرضى و طرق العمل
) من تشريح أنسجة 01وكذلك (  msalpoendioryhTعينة من الأنسجة الحميدة  )02خزعة نسيجية من سرطان الغدة الدرقية من الصنف الأول و ( 
 namuH . وقد تم الكشف عن فيروسخدام عينات الغدة الدرقية لأصحاءالغدة الدرقية العادية التي تم جمعها من أرشيف معهد الطب العدلي/ بابل باست
 .euqinhcet noitazidirbyh utisباستخدام نسخة حساسة للغاية من   81-suriV amollipaP
٪ من مجموعة  53في حين تم الكشف عن  81 - VPH٪ من المرضى مصابين بالفيروس  7.65: من بين أورام الغدة الدرقية الخبيثة نسبة ا  النتائج
٪ إناث  7.23. كان snoitcaer HSI. لم تظهر أي من عينات مجموعة السيطرة    81 - VPH ورم الغدة الدرقية الحميدة مصابين بالفيروس
. ولم تظهر أي دلالة إحصائية بين وجود الفيروس 81 – VPH٪ من الذكور مصابين بفيروس  42، في حين كان 81 – VPH بفيروسمصابات 
 وعمر هؤلاء المرضى .
 .ن يعانون من سرطان الغدة الدرقيةأن له دورا بالمشاركة في التسبب في الإصابة لدى مجموعة المرضى الذي 81 – VPHالاستنتاجات : 
 ,سرطان الغدة الدرقية, التهجين الموضعي81 – VPHت المفتاحية:    الكلما
